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Bisphosphonates, bone, and breast cancer recurrence
Bisphosphonates reduce bone turnover by inhibiting 
osteoclast maturation and function, and are important 
in the prevention of age-related osteoporosis and 
bone fracture,1 in the prevention of complications of 
bone metastases,2 and in the prevention of osteopenia 
and osteoporosis resulting from adjuvant aromatase 
inhibitor therapy of breast cancer.3
Over 125 years ago, in The Lancet, Paget hypothesised 
that the “soil” in which a tumour resides would be 
important for tumour propagation and growth.4 
Interruption of the interaction of tumour micrometastases 
with their microenvironmental “soil” is now a subject of 
intense investigation. Bone is an active microenvironment, 
and, in bone with high turnover, excess osteoclastic activity 
could potentially lead to excess production of growth 
factors, which could aﬀ ect survival of micrometastases.5 
Bisphosphonates, by reducing osteoclast activity, could 
in theory reduce expression of these factors, thereby 
preventing establishment of micrometastatic disease.
Clinical trials of bisphosphonates as adjuvant therapy 
for breast cancer have had mixed results. Clodronate, 
an oral ﬁ rst-generation bisphosphonate, showed a 
disease-free survival beneﬁ t versus placebo in one large 
randomised trial,6 but not in another.7 An early trial of 
zoledronic acid, a more powerful third-generation amino-
bisphosphonate, added to adjuvant aromatase inhibitor 
therapy for postmenopausal women to prevent bone loss, 
showed a non-signiﬁ cant improve ment in disease-free 
survival,3 a secondary endpoint. Larger trials comparing 
zoledronic acid to no therapy in postmenopausal 
women,8 or in premenopausal women made menopausal 
with gonadotropin-releasing hormone agonists,9 
showed signiﬁ cant disease-free survival beneﬁ ts, but 
no beneﬁ t was seen in a large randomised trial of both 
premenopausal and postmenopausal women.10
In The Lancet, the Early Breast Cancer Trialists’ 
Collaborative Group11 presents a meta-analysis of 
randomised trials of bisphosphonates as adjuvant 
systemic therapy for breast cancer. This meta-analysis 
is comprised of individual patient data derived from 
randomised adjuvant bisphosphonate trials in breast 
cancer done over the past 20 years. The analysis received 
data on 18 766 women (18 206 in randomised trials 
of 2–5 years of adjuvant bisphosphonate vs control), 
with a median follow-up of 5·6 years, 3453 ﬁ rst 
recurrences, and 2106 deaths. For all patients, there were 
borderline signiﬁ cant reductions with the addition 
of bisphosphonates at 10 years for distant recurrence 
(20·4% vs 21·8%, rate ratio [RR]=0·92, 95% CI 0·85–0·99; 
2p=0·03), bone recurrence (7·8% vs 9·0%, RR=0·83, 
0·73–0·94; 2p=0·004), breast cancer mortality (16·6% 
vs 18·4%, RR=0·91, 0·83–0·99; 2p=0·04), and all-cause 
mortality (20·8% vs 22·3%, RR=0·92, 0·85–1·00; 2p=0·06). 
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In postmenopausal women, there were highly signiﬁ cant 
reductions with the addition of bisphosphonates at 
10 years for bone recurrence (6·6% vs 8·8%, RR=0·72, 
0·60–0·86; 2p=0·0002) and for breast cancer mortality 
(14·7% vs 18·0%, RR=0·82, 0·73–0·93; 2p=0·002). This 
beneﬁ t was independent of the type of bisphosphonate, 
the schedule of bisphosphonate administration, the 
oestrogen receptor status of the primary tumour, 
the presence of axillary lymph node involvement, and 
the use of concomitant systemic chemotherapy. There 
was no reduction in the incidence of contralateral 
breast cancer or in the risk of metastasis to non-osseous 
sites. In the 13 341 women with available fracture data, 
bisphosphonates reduced the risk of fracture from 7·3% to 
6·3% (RR=0·85, 0·75–0·97; 2p=0·02).
This landmark report on breast cancer treatment 
should lead to widespread adoption of bisphosphonates 
as a standard of care for the adjuvant therapy of 
early-stage breast cancer in postmenopausal women. 
The absolute reduction in the risk of breast cancer 
death at 10 years with the use of bisphosphonates in 
postmenopausal women (3·3%) is similar to the beneﬁ t 
seen with anthracycline polychemotherapy versus non-
anthracycline poly chemotherapy.12 Bisphosphonates, 
in one form or another, are generic and relatively 
inexpensive in most parts of the world. The toxic eﬀ ects 
of these agents are relatively mild (ie, gastrointestinal 
upset, arthralgias, and very uncommon osteonecrosis of 
the jaw).6,10 All bisphosphonates appear to be eﬀ ective, 
as long as they are given for at least 2 years. Given their 
low cost, relatively low toxicity, and overall survival 
beneﬁ t, widespread use of adjuvant bisphosphonates 
for postmenopausal breast cancer has great potential to 
reduce mortality from this disease further.
Should all postmenopausal women with early-stage 
breast cancer receive adjuvant bisphosphonates? 
Bisphosphonate action seems to be bone centric, in that 
bisphosphonates do not appear to prevent contralateral 
breast cancer, locoregional disease, or metastases to 
non-osseous sites. A recent report13 indicating that 
overexpression of lysyl oxidase by primary breast 
cancers can lead to increased bone turnover in the bone 
microenvironmental niche and increased establish-
ment of bone metastases is intriguing, and suggests 
a potential biomarker for response. Increased bone 
turnover after menopause might also explain the 
preferential beneﬁ t of bisphosphonates in reducing 
bone recurrence in post menopausal women. It will be 
interesting to determine if osteoprotogerin analogues 
such as denosumab provide disease-free survival beneﬁ ts 
similar to bisphosphonates in ongoing clinical trials such 
as ABCSG-18,14 in which denosumab signiﬁ cantly reduced 
fracture rates in post menopausal women receiving 
aromatase inhibitors.
This apparent success in altering the natural history of 
breast cancer by modifying the tumour micro environment 
lends great credence to investigational eﬀ orts in breast 
cancer and other cancers attempt ing to understand and 
modify tumour–host micro environmental interactions.
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